Literature DB >> 9181604

Bioavailability of enrofloxacin after oral administration to fed and fasted pigs.

P Nielsen1, N Gyrd-Hansen.   

Abstract

The disposition of enrofloxacin was measured after intravenous and oral administration to pigs. Eight clinically healthy pigs weighing 25 to 40 kg received a dose of 5 mg/kg intravenously and 10 mg/kg orally in both a fasted and a fed condition in a three-way cross-over design. Enrofloxacin was present in plasma for up to 72 hr after both intravenous and oral administration to fasted as well as fed pigs. The steady state volume of distribution was determined to 3.9 +/- 0.5 1/kg body weight which indicates that enrofloxacin was widely distributed in the body. The bioavailability was determined to 83 +/- 13% in fed and to 101 +/- 32% in fasted pigs. Based on the bioavailability and the resulting plasma concentrations it is concluded that a therapeutically active concentration for the most common porcine microbial pathogens are maintained for at least 24 hr after oral administration of 10 mg/kg body weight to fasted as well as to fed pigs. Ciprofloxacin which is an active metabolite of enrofloxacin was observed in plasma samples from all treated pigs, but the concentration never exceeded 0.1 microgram/ml. During the first 24 hr after the administration of enrofloxacin the concentration of the metabolite made up less than 10% of the corresponding concentration of the parent compound.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9181604     DOI: 10.1111/j.1600-0773.1997.tb01967.x

Source DB:  PubMed          Journal:  Pharmacol Toxicol        ISSN: 0901-9928


  8 in total

1.  Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin after intramuscular administration of enrofloxacin in goats.

Authors:  G S Rao; S Ramesh; A H Ahmad; H C Tripathi; L D Sharma; J K Malik
Journal:  Vet Res Commun       Date:  2001-04       Impact factor: 2.459

Review 2.  Effects of food on clinical pharmacokinetics.

Authors:  B N Singh
Journal:  Clin Pharmacokinet       Date:  1999-09       Impact factor: 6.447

Review 3.  Haemophilus parasuis: infection, immunity and enrofloxacin.

Authors:  Nubia Macedo; Albert Rovira; Montserrat Torremorell
Journal:  Vet Res       Date:  2015-10-28       Impact factor: 3.683

4.  Pharmacokinetic and Pharmacodynamic Integration and Modeling of Enrofloxacin in Swine for Escherichia coli.

Authors:  Jianyi Wang; Haihong Hao; Lingli Huang; Zhenli Liu; Dongmei Chen; Zonghui Yuan
Journal:  Front Microbiol       Date:  2016-02-02       Impact factor: 5.640

5.  The impact of therapeutic-dose induced intestinal enrofloxacin concentrations in healthy pigs on fecal Escherichia coli populations.

Authors:  Joren De Smet; Filip Boyen; Siska Croubels; Geertrui Rasschaert; Freddy Haesebrouck; Robin Temmerman; Sofie Rutjens; Patrick De Backer; Mathias Devreese
Journal:  BMC Vet Res       Date:  2020-10-08       Impact factor: 2.741

Review 6.  Enrofloxacin-The Ruthless Killer of Eukaryotic Cells or the Last Hope in the Fight against Bacterial Infections?

Authors:  Łukasz Grabowski; Lidia Gaffke; Karolina Pierzynowska; Zuzanna Cyske; Marta Choszcz; Grzegorz Węgrzyn; Alicja Węgrzyn
Journal:  Int J Mol Sci       Date:  2022-03-26       Impact factor: 5.923

7.  Dispositions of enrofloxacin and its major metabolite ciprofloxacin in Thai swamp buffaloes.

Authors:  Nitwarat Ruennarong; Kannika Wongpanit; Chainarong Sakulthaew; Mario Giorgi; Susumu Kumagai; Amnart Poapolathep; Saranya Poapolathep
Journal:  J Vet Med Sci       Date:  2015-11-20       Impact factor: 1.267

8.  Antibacterial Residue Excretion via Urine as an Indicator for Therapeutical Treatment Choice and Farm Waste Treatment.

Authors:  María Jesús Serrano; Diego García-Gonzalo; Eunate Abilleira; Janire Elorduy; Olga Mitjana; María Victoria Falceto; Alicia Laborda; Cristina Bonastre; Luis Mata; Santiago Condón; Rafael Pagán
Journal:  Antibiotics (Basel)       Date:  2021-06-23
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.